Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Genmab Reaches GSK MAb Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Genmab Reaches GSK MAb Milestone

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genmab has reached a development milestone for ofatumumab (HuMax-CD20) under the terms of its collaboration with GlaxoSmithKline. The milestone triggers a $6 million payment to Genmab as a result of the first patient treated in the Phase II study of ofatumumab in relapsing remitting multiple sclerosis (RRMS).
   
“Our collaboration with GSK continues to progress as both companies work towards providing new treatment options for patients,” said Lisa N. Drakeman, Ph.D., chief executive officer of Genmab. “We are pleased to begin treating patients in the first study of ofatumumab in RRMS, an unpredictable and debilitating disease.”
   
Ofatumumab is a fully human, next generation monoclonal antibody that targets a distinct small loop epitope on the CD20 receptor on the surface of B-cells.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters